RT Journal Article SR Electronic T1 Hydroxychloroquine usage in US patients, their experiences of tolerability and adherence, and implications for treatment: survey results from 3127 patients with SLE conducted by the Lupus Foundation of America JF Lupus Science & Medicine JO Lupus Sci & Med FD Lupus Foundation of America SP e000317 DO 10.1136/lupus-2019-000317 VO 6 IS 1 A1 Daniel J Wallace A1 Karin Tse A1 Leslie Hanrahan A1 Rupert Davies A1 Michelle A Petri YR 2019 UL http://lupus.bmj.com/content/6/1/e000317.abstract AB The majority of patients with SLE in the USA have been prescribed hydroxychloroquine (HCQ). Given more recent guidelines, the availability of only one strength (200 mg tablets) may limit the flexibility and ability to accurately dose patients with lupus. The Lupus Foundation of America undertook a survey to assess the current landscape of HCQ tolerability and adherence.